ARROWHEAD PHARMACEUTICALS, INC. 8-K

What Happened

• Arrowhead Pharmaceuticals, Inc. (ARWR) announced and commented on its fiscal 2026 financial results for the period ended December 31, 2025 via a press release dated February 5, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K filed on February 5, 2026.
• The Form 8‑K reports Item 2.02 (Results of Operations and Financial Condition) and includes the press release as an exhibit rather than filing it as part of the company’s formal Exchange Act disclosures.

Key Details

• Filing date: February 5, 2026 (Form 8‑K reporting Item 2.02).
• Period covered: fiscal 2026 results for the period ended December 31, 2025.
• Exhibit: Press release furnished as Exhibit 99.1 (the filing also includes the Inline XBRL cover page).
• The company states the furnished information is “not deemed filed” under Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.

Why It Matters

• This 8‑K signals that Arrowhead has released its latest earnings/financial results; investors should review the furnished press release for specific metrics (revenue, earnings, cash position, guidance).
• Because the release was furnished (not “filed”), it is provided for investor information but is subject to different legal treatment under the Exchange Act—investors should rely on the press release for detail and await any subsequently filed reports (quarterly/annual filings) for audited or formally filed financial statements.